<html>
<head>
<title>Utah Legislature HB0175</title>
</head>
<body>
<div id="content">
<font face="Arial">
</font><font face="Arial" size="3">1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center><b>OPIOID ABUSE PREVENTION AND TREATMENT</b></center><br/>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><center>AMENDMENTS</b></font><font face="Arial" size="2"></center><br/>3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center>2017 GENERAL SESSION</center><br/>4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center>STATE OF UTAH</center><br/>5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center></font><font face="Arial" size="3"><b>Chief Sponsor:  Steve Eliason</b></font><font face="Arial" size="2"></center><br/>6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<center></font><font face="Arial" size="3">Senate Sponsor: </font><font face="Arial" size="2"></font><font face="Arial" size="3">  Brian E. Shiozawa</font><font face="Arial" size="2"></center><br/>7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <hr style="width:90%; padding: 0; border: none; border-top: thick double #333; color: #333; text-align: right" /><br/>8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>LONG TITLE</b><br/>9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>General Description:</b><br/>10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This bill requires controlled substance prescribers to receive training in a nationally<br/>11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;recognized opioid abuse screening method and requires reimbursement for the<br/>12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;screening services.<br/>13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Highlighted Provisions:</b><br/>14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This bill:<br/>15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9656;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;requires controlled substance prescribers to receive training in a nationally<br/>16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;recognized opioid abuse screening method;<br/>17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9656;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;permits controlled substance prescribers to fulfill continuing education requirements<br/>18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;through training in the screening method;<br/>19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9656;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;permits controlled substance prescribers who receive a DATA 2000 waiver to use<br/>20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the waiver to fulfill certain continuing education requirements;<br/>21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9656;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;requires Medicaid reimbursement to health care providers for screening services;<br/>22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9656;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;requires the Public Employees' Benefit and Insurance Program to reimburse health<br/>23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;care providers for screening services; and<br/>24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9656;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;makes technical changes.<br/>25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Money Appropriated in this Bill:</b><br/>26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None<br/>27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Other Special Clauses:</b><br/><hr>28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None<br/>29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Utah Code Sections Affected:</b><br/>30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AMENDS:<br/>31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#58-37-6.5">58-37-6.5</a></b>, as repealed and reenacted by Laws of Utah 2013, Chapter 450<br/>32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ENACTS:<br/>33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#26-18-21">26-18-21</a></b>, Utah Code Annotated 1953<br/>34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="#49-20-414">49-20-414</a></b>, Utah Code Annotated 1953<br/>35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <hr style="width:90%; padding: 0; border: none; border-top: thick double #333; color: #333; text-align: right" /><br/>36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>Be it enacted by the Legislature of the state of Utah:</i><br/>37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 1.  Section <b>26-18-21</b><a name="26-18-21"></a> is enacted to read:<br/>38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26-18-21.</u></b>  <b>Screening, Brief Intervention, and Referral to Treatment Medicaid</b><br/>39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>reimbursement.</b><br/>40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1)  As used in this section:</u><br/>41&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  "Controlled substance prescriber" means a controlled substance prescriber, as that</u><br/>42&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>term is defined in Section <a href="#58-37-6.5">58-37-6.5</a>, who:</u><br/>43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(i)  has a record of having completed SBIRT training, in accordance with Subsection</u><br/>44&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><a href="#58-37-6.5">58-37-6.5</a>(2), before providing the SBIRT services; and</u><br/>45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(ii)  is a Medicaid enrolled health care provider.</u><br/>46&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  "SBIRT" means the same as that term is defined in Section <a href="#58-37-6.5">58-37-6.5</a>.</u><br/>47&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2)  The department shall reimburse a controlled substance prescriber who provides</u><br/>48&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>SBIRT services to a Medicaid enrollee who is 13 years of age or older for the SBIRT services.</u><br/>49&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 2.  Section <b>49-20-414</b><a name="49-20-414"></a> is enacted to read:<br/>50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;49-20-414.</u></b>  <b>Screening, Brief Intervention, and Referral to Treatment program</b><br/>51&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>reimbursement.</b><br/>52&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(1)  As used in this section:</u><br/>53&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(a)  "Controlled substance prescriber" means a controlled substance prescriber, as that</u><br/>54&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>term is defined in Section <a href="#58-37-6.5">58-37-6.5</a>, who:</u><br/>55&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(i)  has a record of having completed SBIRT training, in accordance with Subsection</u><br/>56&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><a href="#58-37-6.5">58-37-6.5</a>(2), before providing the SBIRT services; and</u><br/>57&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(ii)  is a program enrolled controlled substance prescriber.</u><br/>58&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  "SBIRT" means the same as that term is defined in Section <a href="#58-37-6.5">58-37-6.5</a>.</u><br/><hr>59&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(2)  The health program offered to the state employee risk pool under Section</u><br/>60&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><a href="http://le.utah.gov/UtahCode/SectionLookup.jsp?section=49-20-202&session=2017GS">49-20-202</a> shall reimburse a controlled substance prescriber who provides SBIRT services to a</u><br/>61&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>covered individual who is 13 years of age or older for the SBIRT services.</u><br/>62&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 3.  Section <b>58-37-6.5</b><a name="58-37-6.5"></a> is amended to read:<br/>63&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>58-37-6.5.</b>   <b>Continuing education for controlled substance prescribers.</b><br/>64&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)  For the purposes of this section:<br/>65&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)  "Controlled substance prescriber" means an individual, other than a veterinarian,<br/>66&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;who:<br/>67&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)  is licensed to prescribe a controlled substance under Title 58, Chapter 37, Utah<br/>68&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Controlled Substances Act; and<br/>69&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)  possesses the authority, in accordance with the individual's scope of practice, to<br/>70&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;prescribe schedule II controlled substances and schedule III controlled substances that are<br/>71&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;applicable to opioid narcotics, hypnotic depressants, or psychostimulants.<br/>72&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b)  "D.O." means an osteopathic physician and surgeon licensed under Title 58,</u><br/>73&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Chapter 68, Utah Osteopathic Medical Practice Act.</u><br/>74&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(b)</strike>] <u>(c)</u>  "FDA" means the United States Food and Drug Administration.<br/>75&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(c)</strike>] <u>(d)</u>  "M.D." means a physician and surgeon licensed under Title 58, Chapter 67,<br/>76&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Utah Medical Practice Act.<br/>77&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<strike>(d)  "D.O." means an osteopathic physician and surgeon licensed under Title 58,</strike><br/>78&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strike>Chapter 68, Utah Osteopathic Medical Practice Act.</strike>]<br/>79&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(e)  "SBIRT" means the Screening, Brief Intervention, and Referral to Treatment</u><br/>80&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>approach used by the federal Substance Abuse and Mental Health Services Administration or</u><br/>81&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>defined by the division, in consultation with the Division of Substance Abuse and Mental</u><br/>82&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Health, by administrative rule, in accordance with Title 63G, Chapter 3, Utah Administrative</u><br/>83&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Rulemaking Act.</u><br/>84&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) <u>(a)</u>  Beginning with the licensing period that begins after January 1, 2014, as a<br/>85&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;condition precedent for license renewal, each controlled substance prescriber shall complete at<br/>86&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;least four continuing education hours per licensing period that satisfy the requirements of<br/>87&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsections (3) and (4).<br/>88&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(b) (i)  Beginning with the licensing period that begins after January 1, 2024, as a</u><br/>89&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>condition precedent for license renewal, each controlled substance prescriber shall complete at</u><br/><hr>90&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>least 3.5 continuing education hours in an SBIRT-training class that satisfies the requirements</u><br/>91&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>of Subsection (5).</u><br/>92&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(ii)  Completion of the SBIRT-training class, in compliance with Subsection (2)(b)(i),</u><br/>93&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>fulfills the continuing education hours requirement in Subsection (4) for the licensing period in</u><br/>94&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>which the class was completed.</u><br/>95&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(iii)  A controlled substance prescriber:</u><br/>96&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(A)  need only take the SBIRT-training class once during the controlled substance</u><br/>97&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>prescriber's licensure in the state; and</u><br/>98&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(B)  shall provide a completion record of the SBIRT-training class in order to be</u><br/>99&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>reimbursed for SBIRT services to patients, in accordance with Section <a href="#26-18-21">26-18-21</a> and Section</u><br/>100&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><a href="#49-20-414">49-20-414</a>.</u><br/>101&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)  As provided in Subsection <a href="http://le.utah.gov/UtahCode/SectionLookup.jsp?section=58-37f-402&session=2017GS">58-37f-402</a>(8), the online tutorial and passing the online<br/>102&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;test described in Section <a href="http://le.utah.gov/UtahCode/SectionLookup.jsp?section=58-37f-402&session=2017GS">58-37f-402</a> shall count as 1/2 hour of continuing professional<br/>103&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;education under Subsection (2) per licensing period.<br/>104&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)  A controlled substance prescriber shall complete at least 3.5 hours of continuing<br/>105&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;education [<strike>hours</strike>] in one or more controlled substance prescribing classes, except dentists who<br/>106&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall complete at least [<strike>2 such</strike>] <u>two</u> hours, that satisfy the requirements of Subsections (5) and<br/>107&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7).<br/>108&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)  A controlled substance prescribing class shall:<br/>109&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)  satisfy the division's requirements for the continuing education required for the<br/>110&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;renewal of the controlled substance prescriber's respective license type;<br/>111&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)  be delivered by an accredited or approved continuing education provider<br/>112&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;recognized by the division as offering continuing education appropriate for the controlled<br/>113&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;substance prescriber's respective license type; and<br/>114&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)  include a postcourse knowledge assessment.<br/>115&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)  An M.D. or D.O. completing continuing professional education hours under<br/>116&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsection (4) shall complete those hours in classes that qualify for the American Medical<br/>117&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Association Physician's Recognition Award Category 1 Credit.<br/>118&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7)  The 3.5 hours of the controlled substance prescribing classes under Subsection (4)<br/>119&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall include educational content covering the following:<br/>120&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)  the scope of the controlled substance abuse problem in Utah and the nation;<br/><hr>121&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)  all elements of the FDA Blueprint for Prescriber Education under the FDA's<br/>122&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Extended-Release and Long-Acting Opioid Analgesics Risk Evaluation and Mitigation<br/>123&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Strategy, as published July 9, 2012, or as it may be subsequently revised;<br/>124&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)  the national and Utah-specific resources available to prescribers to assist in<br/>125&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;appropriate controlled substance and opioid prescribing;<br/>126&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)  patient record documentation for controlled substance and opioid prescribing; and<br/>127&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)  office policies, procedures, and implementation.<br/>128&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(8) (a)  The division, in consultation with the Utah Medical Association Foundation,<br/>129&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall determine whether a particular controlled substance prescribing class satisfies the<br/>130&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;educational content requirements of Subsections (5) and (7) for an M.D. or D.O.<br/>131&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)  The division, in consultation with the applicable professional licensing boards,<br/>132&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall determine whether a particular controlled substance prescribing class satisfies the<br/>133&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;educational content requirements of Subsections (5) and (7) for a controlled substance<br/>134&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;prescriber other than an M.D. or D.O.<br/>135&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)  The division may by rule establish a committee that may audit compliance with the<br/>136&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Utah Risk Evaluation and Mitigation Strategy (REMS) Educational Programming Project<br/>137&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;grant, that satisfies the educational content requirements of Subsections (5) and (7) for a<br/>138&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;controlled substance prescriber.<br/>139&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(9)  A controlled substance prescribing class required under this section:<br/>140&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)  may be held:<br/>141&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)  in conjunction with other continuing professional education programs; and<br/>142&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)  online; and<br/>143&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)  does not increase the total number of state-required continuing professional<br/>144&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;education hours required for prescriber licensing.<br/>145&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(10)  The division may establish rules, in accordance with Title 63G, Chapter 3, Utah<br/>146&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Administrative Rulemaking Act, to implement this section.<br/>147&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(11)  A controlled substance prescriber who, on or after July 1, 2017, obtains a waiver</u><br/>148&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>to treat opioid dependency with narcotic medications, in accordance with the Drug Addiction</u><br/>149&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Treatment Act of 2000, 21 U.S.C. Sec. 823 et seq., may use the waiver to satisfy the 3.5 hours</u><br/>150&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>of the continuing education requirement under Subsection (4) for two consecutive licensing</u><br/>151&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>periods.</u><br/><hr><br/><hr style="width:90%; color: #333; text-align: right" /><br/><hr style="width:90%; color: #333; text-align: right" /><br/><br/><b>Legislative Review Note<br/>Office of Legislative Research and General Counsel</b>
</font>
</div>
</body>
</html>
